Evolent Health (NYSE: EVH) reported Q2 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $222.1 million versus the consensus estimate of $216.92 million.

Business Outlook:

Full Year 2021 Guidance

Revenue for the year ending December 31, 2021 is expected to be in the range of approximately $870 million to $900 million, compared to previous guidance of $845 million to $880 million.

Adjusted EBITDA is expected to be in the range of approximately $50 million to $58 million, compared to previous guidance of $42 million to $52 million.

Third Quarter 2021 Guidance

For the three months ending September 30, 2021, revenue is expected to be in the range of approximately $215 million to $230 million. Adjusted EBITDA is expected to be in the range of approximately $11 million to $15 million.

This "Business Outlook" section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").

For earnings history and earnings-related data on Evolent Health (EVH) click here.